Publications

• Private Equity Report: 2024 Outlook
  February 2024
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Paul S. Bird
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Charu A. Chandrasekhar
  ,
  Jennifer L. Chu
  ,
  Luke P. Eldridge
  ,
  Luke Dembosky
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Avi Gesser
  ,
  Andrew J. Gershon
  ,
  Nia I. Goodman
  ,
  David Grosgold
  ,
  Jyotin Hamid
  ,
  Ted Hassi
  ,
  Morgan J. Hayes
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Robert B. Kaplan
  ,
  M. Natasha Labovitz
  ,
  Jonathan F. Lewis
  ,
  Sidney P. Levinson
  ,
  Andrew M. Levine
  ,
  Erez Liebermann
  ,
  Timothy McIver
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Marc Ponchione
  ,
  Ryan T. Rafferty
  ,
  Natalie L. Reid
  ,
  Julie M. Riewe
  ,
  Kevin Rinker
  ,
  Samantha J. Rowe
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Kevin M. Schmidt
  ,
  Scott B. Selinger
  ,
  Aly Love Simons
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  Steven J. Slutzky
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Erica S. Weisgerber
  ,
  Kyra K. Bromley
  ,
  Alison E. Buckley-Serfass
  ,
  Jennifer R. Cestaro
  ,
  Stuart Hammer
  ,
  Jin-Hyuk Jang
  ,
  Wen-Wei Lai
  ,
  Michael P. McGuigan
  ,
  Sheena Paul
  ,
  Melissa Runsten
  ,
  Tricia Bozyk Sherno
  ,
  Ulysses Smith
  ,
  Sergio Torres
  ,
  Elie J. Worenklein
  ,
  Adam Aukland-Peck
  ,
  Josephine Chen
  ,
  Perpétua B. Chéry
  ,
  Paul Eastham
  ,
  Isabelle Glimcher
  ,
  Yiran Ji
  ,
  Maryam Kanna
  ,
  Leah Martin
  ,
  Sophie Michalski
  ,
  Diana Moise
  ,
  David J. Swiedler
  ,
  Perri M. Weinstein
  ,
  Nathan R. Hogan
• Chevron Under Fire: What Healthcare and Life Sciences Investors Should Know
  19 January 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Zoe Jacoby
  ,
  Adriana Kranjac
  ,
  Kaitlyn McGill
• Top 10 Healthcare and Life Sciences Issues to Watch in 2024
  4 January 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Ilya Balabanovsky
  ,
  Michael L. Cederblom
  ,
  Margaret Howard
  ,
  Chaim Lapp
  ,
  Hannah R. Levine
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
• CMS Announces First Ten Medicare Part D Drugs Subject to Price Negotiations
  6 October 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Michael L. Cederblom
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• California Seeks to Increase Healthcare Workers’ Minimum Wage to $25/hour
  21 August 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Meir D. Katz
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Michael L. Cederblom
• Artificial Intelligence in Healthcare: Balancing Risks and Rewards
  31 July 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Avi Gesser
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Caroline P. Geiger
  ,
  Kim T. Le
  ,
  Tigist Kassahun
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Mengyi Xu
  ,
  Michael L. Cederblom
• The FTC’s Warning to Online Marketplaces: Comply with the New INFORM Consumers Act or Face Civil Penalties
  27 June 2023
  Megan K. Bannigan
  ,
  Paul D. Rubin
  ,
  Christopher S. Ford
  ,
  Jared I. Kagan
  ,
  Melissa Runsten
  ,
  Kate Saba
• FDA Guidance Offers Additional Clarity for Decentralized Clinical Trials
  30 May 2023
  Andrew L. Bab
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Michael L. Cederblom
• Artificial Intelligence and the Life Sciences Industry: FDA and FTC Regulatory Update
  16 May 2023
  Andrew L. Bab
  ,
  Avi Gesser
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
• Legal Dispute Surrounding Abortion Pill Has Significant Implications for Broader Healthcare Industry
  9 May 2023
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Shannon Rose Selden
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Prakriti Luthra
  ,
  Melissa Runsten
• Private Equity Report: 2023 Outlook
  January 2023
  Catherine Amirfar
  ,
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Jason Auerbach
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Kara Brockmeyer
  ,
  Geoffrey P. Burgess
  ,
  Lawrence K. Cagney
  ,
  Andrew J. Ceresney
  ,
  Jennifer L. Chu
  ,
  Alexander R. Cochran
  ,
  Eric Dinallo
  ,
  Christopher Dortschy
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Jyotin Hamid
  ,
  Ted Hassi
  ,
  Morgan J. Hayes
  ,
  Gareth Hughes
  ,
  Peter J. Irwin
  ,
  Mark Johnson
  ,
  Eric T. Juergens
  ,
  Rafael Kariyev
  ,
  Meir D. Katz
  ,
  Satish M. Kini
  ,
  M. Natasha Labovitz
  ,
  Henry Lebowitz
  ,
  Maurizio Levi-Minzi
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Marilyn A. Lion
  ,
  Timothy McIver
  ,
  John (Jay) Neukom
  ,
  Benjamin R. Pedersen
  ,
  Marc Ponchione
  ,
  Nicholas F. Potter
  ,
  Ryan T. Rafferty
  ,
  Julie M. Riewe
  ,
  Samantha J. Rowe
  ,
  Paul D. Rubin
  ,
  Scott B. Selinger
  ,
  Jane Shvets
  ,
  Steven J. Slutzky
  ,
  Patricia Volhard
  ,
  Erica S. Weisgerber
  ,
  Barbara N. Barath
  ,
  Alison E. Buckley-Serfass
  ,
  Zhiyan Cao
  ,
  Robert T. Dura
  ,
  Robert M. Fettman
  ,
  Samuel Fung
  ,
  Caroline P. Geiger
  ,
  Andrew J. Gershon
  ,
  Jin-Hyuk Jang
  ,
  Stuart Hammer
  ,
  Kim T. Le
  ,
  Michael P. McGuigan
  ,
  Sheena Paul
  ,
  Tricia Bozyk Sherno
  ,
  Jennifer Wheater
  ,
  John Young
  ,
  Jeffrey P. Cunard
  ,
  Ulysses Smith
  ,
  Jennifer R. Cestaro
  ,
  Paul Eastham
  ,
  Isabel Espinosa de los Reyes
  ,
  Jay E. Evans
  ,
  Christopher Gossage
  ,
  Berk Guler
  ,
  Yiran Ji
  ,
  Samuel D. Krawiecz
  ,
  Chaim Lapp
  ,
  Stacy S. Lee
  ,
  Lucy Litt
  ,
  Emily MacKay
  ,
  Alma M. Mozetič
  ,
  Ezra Newman
  ,
  Melissa Runsten
  ,
  Sergio Torres
  ,
  George Tan
  ,
  Tiffany Wu
  ,
  Emma Macfarlane
  ,
  Sarah Min
  ,
  Matthew Stromecki
  ,
  Massy Vainshtein
• Top 15 Healthcare and Life Sciences Issues to Watch in 2023
  9 January 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Elie J. Worenklein
  ,
  Samuel J. Allaman
  ,
  Adam Aukland-Peck
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Adam C. Saunders
  ,
  Adrian St. Francis
  ,
  Emily G. Dennan
  ,
  Michael L. Cederblom
  ,
  Micah A. Rubin
• American Bar Association: Competitor Advertising Challenges: Considerations for FDA-Regulated Companies
  28 September 2022
  American Bar Association
  Paul D. Rubin
  ,
  Melissa Runsten
• National Association of Attorneys General’s 2022 Presidential Summit: Tech Threats and Tools
  23 August 2022
  Courtney M. Dankworth
  ,
  Eric Dinallo
  ,
  Avi Gesser
  ,
  Paul D. Rubin
  ,
  Jehan A. Patterson
  ,
  Melissa Runsten
• Texas Federal Judge Sides with Providers in “No Surprises Act” Ruling
  1 March 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Adriana Kranjac
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• NYU Compliance & Enforcement Blog: A New Era of Federal Trade Commission (“FTC”) Privacy and Cybersecurity Oversight: Top Ten Things Companies Should Know When Assessing FTC Compliance and Exposure
  26 January 2022
  NYU Compliance & Enforcement Blog
  Luke Dembosky
  ,
  Avi Gesser
  ,
  Ted Hassi
  ,
  Paul D. Rubin
  ,
  Jim Pastore
  ,
  Johanna N. Skrzypczyk
  ,
  Leah Martin
  ,
  Melissa Runsten
  ,
  Christopher S. Ford
• Law360: What Stablecoin Industry Can Expect From Congress In 2022
  25 January 2022
  Law360
  Luke Dembosky
  ,
  Avi Gesser
  ,
  Ted Hassi
  ,
  Paul D. Rubin
  ,
  Jim Pastore
  ,
  Johanna N. Skrzypczyk
  ,
  Leah Martin
  ,
  Melissa Runsten
  ,
  Christopher S. Ford
• 2021/2022 Private Equity Year-End Review and Outlook
  January 2022
  Jonathan Adler
  ,
  Catherine Amirfar
  ,
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Geoffrey P. Burgess
  ,
  Ezra Borut
  ,
  Andrew J. Ceresney
  ,
  Jennifer L. Chu
  ,
  Jeffrey P. Cunard
  ,
  Alexander R. Cochran
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Morgan J. Hayes
  ,
  Eric T. Juergens
  ,
  Maurizio Levi-Minzi
  ,
  Nicholas P. Pellicani
  ,
  Ryan T. Rafferty
  ,
  Julie M. Riewe
  ,
  Scott B. Selinger
  ,
  Marc Ponchione
  ,
  Thomas Smith
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Richard Ward
  ,
  Alisa A. Waxman
  ,
  Marshal L. Bozzo
  ,
  Christopher Dortschy
  ,
  Andrew J. Gershon
  ,
  Emily F. Huang
  ,
  Jennifer Wheater
  ,
  Dominic Blaxill
  ,
  Charles Cartiglia
  ,
  Robert T. Dura
  ,
  Matthew J. Sacco
  ,
  Sheng Shao
  ,
  Sergio Torres
  ,
  Charlotte A. Walkovik
  ,
  Paul Eastham
  ,
  Christopher Gossage
  ,
  Robert B. Kaplan
  ,
  Sheena Paul
  ,
  John Young
  ,
  Jin-Hyuk Jang
  ,
  Lukas Ott
  ,
  Andrew M. Levine
  ,
  Stuart Hammer
  ,
  Ulysses Smith
  ,
  Luke Dembosky
  ,
  Avi Gesser
  ,
  Michael R. Roberts
  ,
  Peter J. Irwin
  ,
  Ina C. Popova
  ,
  Samantha J. Rowe
  ,
  M. Natasha Labovitz
  ,
  Sidney P. Levinson
  ,
  Paul D. Rubin
  ,
  Eric Dinallo
  ,
  Marilyn A. Lion
  ,
  Jacob W. Stahl
  ,
  Nicholas F. Potter
  ,
  Kim T. Le
  ,
  Adam Aukland-Peck
  ,
  Melissa Runsten
  ,
  Matthew Mrozek
  ,
  Michael C. Godbe
  ,
  Christel Y. Tham
  ,
  Lisa Wang Lachowicz
  ,
  Yiran Ji
• A New Era of Federal Trade Commission (“FTC”) Privacy and Cybersecurity Oversight: Top Ten Things Companies Should Know When Assessing FTC Compliance and Exposure
  12 January 2022
  Luke Dembosky
  ,
  Ted Hassi
  ,
  Avi Gesser
  ,
  Jim Pastore
  ,
  Paul D. Rubin
  ,
  Johanna N. Skrzypczyk
  ,
  Christopher S. Ford
  ,
  Leah Martin
  ,
  Melissa Runsten
• Senate Again Rejects SAFE Banking Act, Extending Financial Institutions’ Compliance Quandary
  22 December 2021
  Satish M. Kini
  ,
  Paul D. Rubin
  ,
  Aseel M. Rabie
  ,
  Melissa Runsten
  ,
  Zoë Zissu
• “Non-Toxic” Advertising Claims Can Lead to Toxic Litigation
  30 September 2021
  Megan K. Bannigan
  ,
  David H. Bernstein
  ,
  Paul D. Rubin
  ,
  Jared I. Kagan
  ,
  Melissa Runsten
• Senators Release Draft Marijuana Reform Bill, Setting Stage for Potential Congressional Action
  23 July 2021
  Satish M. Kini
  ,
  Winston M. Paes
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
• The Nature of “Natural” Advertising Claims
  21 July 2021
  Megan K. Bannigan
  ,
  David H. Bernstein
  ,
  Paul D. Rubin
  ,
  Timothy Cuffman
  ,
  Jared I. Kagan
  ,
  Melissa Runsten
• Flurry of New FTC Rules and Policies Signals Era of Aggressive Enforcement Despite Recent Supreme Court Defeat
  13 July 2021
  Ted Hassi
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Leah Martin
  ,
  Melissa Runsten
• ESG for Consumer Product Brands: Whitewashing the Greenwash—Identifying and Reducing Greenwashing Risk
  9 June 2021
  Megan K. Bannigan
  ,
  David H. Bernstein
  ,
  Paul D. Rubin
  ,
  Jared I. Kagan
  ,
  Melissa Runsten
• Unanimous Supreme Court Curtails the Federal Trade Commission’s Authority to Obtain Monetary Remedies in Federal Court
  26 April 2021
  Ted Hassi
  ,
  Paul D. Rubin
  ,
  Leah Martin
  ,
  Melissa Runsten
  ,
  Adam C. Saunders
• Law360: Lessons From Federal Fraud Charges Against UBiome
  16 April 2021
  Law360
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
  ,
  Hannah R. Levine
• Pharm Exec: The American Rescue Plan Act of 2021: Pharmaceutical Industry Impact
  23 March 2021
  Pharm Exec
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• The American Rescue Plan Act of 2021: Implications for Healthcare and Life Sciences Companies
  12 March 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Benjamin Leb
• Proposed Elimination of Medicaid Rebate Cap Could Negatively Impact Innovator Pharmaceutical Industry
  11 February 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Biden Takes Aim at Trump Administration Healthcare Policies
  2 February 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Compliance & Enforcement: Destruction Emerges as a Powerful Enforcement Measure for AI: FTC Requires Company to Delete Models Trained with Improperly Utilized Consumer Data
  22 January 2021
  Compliance & Enforcement:
  Avi Gesser
  ,
  Jim Pastore
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
• Destruction Emerges as a Powerful Enforcement Measure for AI: FTC Requires Company to Delete Models Trained with Improperly Utilized Consumer Data
  19 January 2021
  Avi Gesser
  ,
  Jim Pastore
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
• Consolidated Appropriations Act: Implications for Healthcare and Life Sciences Companies
  30 December 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• The Trump Administration’s Final Drug Pricing Hurrah—Will It Last?
  24 November 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• COVID-19 Vaccines: FDA Regulatory Timeline and Next Steps Prior to Widespread Distribution
  20 November 2020
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Kevin Rinker
  ,
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jennifer L. Chu
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Federal Government Shines Spotlight on Speaker Programs
  20 November 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Columbia Blue Sky Blog: Debevoise & Plimpton Discusses State Marijuana Initiatives and Financial Institutions
  12 November 2020
  Columbia Blue Sky Blog
  Satish M. Kini
  ,
  Winston M. Paes
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
• A Green Wave: State Marijuana Initiatives Create Compliance Challenges for Financial Institutions and Impetus for Possible Federal Action
  10 November 2020
  Satish M. Kini
  ,
  Winston M. Paes
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
• The Potential Impact of a Biden Administration on Life Sciences, Healthcare, and Consumer Product Companies and Investors
  2 November 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Third Circuit Strikes Another Blow Against the FTC’s Preferred Enforcement Power, Setting the Stage for a Supreme Court Showdown
  5 October 2020
  Andrew L. Bab
  ,
  David H. Bernstein
  ,
  Ted Hassi
  ,
  Paul D. Rubin
  ,
  Leah Martin
  ,
  Melissa Runsten
• Providers, Investors Need Clear Post-COVID Telehealth Picture
  22 September 2020
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Bloomberg Law: Providers, Investors Need Clear Post-Covid Telehealth Picture
  16 September 2020
  Bloomberg Law
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
  ,
  Kim T. Le
• Bloomberg Law: Providers, Investors Need Clear Post-Covid Telehealth Picture
  16 September 2020
  Bloomberg Law
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
  ,
  Kim T. Le
• Trump’s Newest Drug Pricing Executive Order: Still Much More Bark than Bite
  16 September 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• HHS Announces Additional CARES Act Funding for Qualifying Providers
  4 August 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• HHS Issues Additional Guidance on Qualifications for CARES Act Funding
  8 May 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Appropriations for Healthcare Providers Related to COVID-19
  30 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• New Appropriation for Healthcare Providers
  24 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Announces Additional Funding for Healthcare Providers Impacted by COVID-19
  23 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Distributing $30 Billion in Grants to Medicare Providers
  10 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CMS Announces Intent to Provide $30 Billion to Medicare Providers
  9 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• The Federal Government Throws a Lifeline to Medicare Providers and Suppliers
  30 March 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CARES Act: Implications for Healthcare and Life Science Companies and Investors
  27 March 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19: CMS Expands Medicare Coverage for Telehealth Services amid Public Health Emergency
  20 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19: FDA Developments and Legal Considerations for Healthcare and Life Science Companies and Investors
  17 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Suchita Mandavilli Brundage
  ,
  Melissa Runsten
• Indian Pharma: Congress and FDA Continue Scrutiny of Foreign Drug Companies with Heightened Focus on Companies Located in India
  12 February 2020
  Andrew L. Bab
  ,
  Geoffrey P. Burgess
  ,
  Jennifer L. Chu
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Suchita Mandavilli Brundage
  ,
  Melissa Runsten
• USDA Issues Long-Awaited Hemp Production Regulations
  31 October 2019
  Satish M. Kini
  ,
  Paul D. Rubin
  ,
  David Sarratt
  ,
  Melissa Runsten
• Law360: Drugmaker Fine Shows SEC's Renewed Disclosure Focus
  30 August 2019
  Law360
  Andrew J. Ceresney
  ,
  Paul M. Rodel
  ,
  Paul D. Rubin
  ,
  Jonathan R. Tuttle
  ,
  Melissa Runsten
• Seventh Circuit Strikes a Blow Against the FTC’s Preferred Enforcement Power
  28 August 2019
  David H. Bernstein
  ,
  Luke Dembosky
  ,
  Ted Hassi
  ,
  Paul D. Rubin
  ,
  Leah Martin
  ,
  Melissa Runsten
• SEC Charges Pharmaceutical Company for Violation of Regulation FD, Reinforcing Need to Establish Policies for Handling Material Non-Public Information
  23 August 2019
  Andrew J. Ceresney
  ,
  Paul M. Rodel
  ,
  Paul D. Rubin
  ,
  Jonathan R. Tuttle
  ,
  Melissa Runsten
• CMS Issues Final Rule Requiring Disclosure of Drug and Biologic “List Prices” in Television Advertisements: Challenges Associated with Lanham Act Enforcement and First Amendment Implications
  16 May 2019
  David H. Bernstein
  ,
  Jyotin Hamid
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Private Equity Guide to Consumer Product Investing Under the Trump Administration: Food and Drug Administration (FDA) Developments
  18 April 2019
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Michael Diz
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kevin M. Schmidt
  ,
  Melissa Runsten
• The Third Circuit Sharply Curtails the FTC’s Preferred Enforcement Power
  1 March 2019
  David H. Bernstein
  ,
  Luke Dembosky
  ,
  Ted Hassi
  ,
  Paul D. Rubin
  ,
  Leah Martin
  ,
  Melissa Runsten
• 2018 Farm Bill to Lift Federal Prohibition on Hemp Production, but State Laws May Restrict Certain Activities
  14 December 2018
  Satish M. Kini
  ,
  Paul D. Rubin
  ,
  David Sarratt
  ,
  Melissa Runsten
• Medical Device Cybersecurity Report Advancing Coordinated Vulnerability Disclosure
  4 December 2018
  Luke Dembosky
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• New Congress Brings Heightened Risk of Investigations for Life Sciences Companies
  19 November 2018
  David A. O'Neil
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CMS’ Proposed Rule Regarding Disclosure of Drug “List Prices” in Television Ads: Needed Transparency or Recipe for Confusion?
  23 October 2018
  Andrew L. Bab
  ,
  David H. Bernstein
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Jared I. Kagan
  ,
  Melissa Runsten
• Private Equity Guide to Life Sciences Investing Under the Trump Administration: Food and Drug Administration (FDA) Developments
  15 March 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
• T.H. v. Novartis: Implications for Companies That Have Sold or Are Considering Selling the Rights to Innovator Drugs
  19 January 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl